Etripamil Nasal Spray

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is pioneering patient-administered therapies for episodic cardiovascular conditions, with its lead candidate etripamil representing a potential paradigm shift in the acute treatment of PSVT. The company has advanced etripamil through multiple Phase 3 clinical trials and is preparing for regulatory submissions. Their strategy focuses on leveraging a self-administered nasal spray formulation to empower patients and reduce healthcare system burdens associated with emergency care for acute arrhythmias.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is pioneering patient-administered therapies for episodic cardiovascular conditions, with its lead candidate etripamil representing a potential paradigm shift in the acute treatment of PSVT. The company has advanced etripamil through multiple Phase 3 clinical trials and is preparing for regulatory submissions. Their strategy focuses on leveraging a self-administered nasal spray formulation to empower patients and reduce healthcare system burdens associated with emergency care for acute arrhythmias.

Therapeutic Areas